MomsSpaghetti
1時間前
Good listen... let's remind our self's of one thing... because the episode title is garbage.
While lysergic acid diethylamide (LSD) itself is not patentable due to its long-standing existence, MindMed has developed MM-120, a proprietary, pharmaceutically optimized form of LSD. To protect their innovation, MindMed has secured patents on specific formulations and delivery methods of MM-120. Notably, in July 2024, the United States Patent and Trademark Office (USPTO) issued a patent covering the MM-120 Orally Disintegrating Tablet (ODT) formulation. This patent includes claims on the pharmaceutical formulation, manufacturing methods, and treatment methods for MM-120 ODT, extending MindMed’s intellectual property protection through 2041. ?
Additionally, MindMed holds exclusive rights to Catalent’s Zydis ODT fast-dissolve technology for all salt and polymorphic forms of lysergide (LSD) for pharmaceutical use in several regions, including the United States, the United Kingdom, the European Union, Switzerland, Israel, and Canada. ? This advanced formulation aims to offer rapid absorption, improved bioavailability, and reduced gastrointestinal side effects, potentially providing a unique clinical profile for MM-120.
By focusing on these proprietary formulations and delivery technologies, MindMed establishes a competitive advantage and safeguards its developments in the therapeutic application of LSD derivatives.
Having said that... we are moving into phase 3 and with lots of positive push from prior trials. The data proves there is something here. Risk mostly has been removed.
We are going to rebound. MindMed is a winner in this space. It's only a matter of time.
MomsSpaghetti
4日前
New Association Launches to Expand Patient Access to Psychedelic Medicines
https://www.prnewswire.com/news-releases/new-association-launches-to-expand-patient-access-to-psychedelic-medicines-302311365.html
News provided by
Association for Prescription Psychedelics
Nov 20, 2024, 06:56 ET
Share this article
Organization Will Educate Policymakers and Advocate for the Development of Safe and Effective Prescription Psychedelics
WASHINGTON, Nov. 20, 2024 /PRNewswire/ -- The Association for Prescription Psychedelics (APP) announced its launch today to integrate proven, efficacious, and evidence-based prescription psychedelic medicines into the health care system for eligible patients across the country.
APP will serve as a trusted and recognized voice on prescription psychedelics and highlight how government-sponsored research, public-private partnerships, patient centric treatment, and health care infrastructure investments can support this innovative area of medicine.
"There's a tremendous opportunity to address the unmet needs of patients across the country who are experiencing a wide range of health challenges by expanding access to psychedelic medicines," said Jon Kostas, Executive Director of APP and Chief Executive Officer of Apollo Pact. "The Association for Prescription Psychedelics will serve as the leading voice for clinical, evidence-based psychedelic medicines and treatments administered by licensed, experienced, and highly trained professionals in the medical community."
APP will be guided by prominent researchers and academics from the University of Alabama at Birmingham, Heffter Research Institute, University of Wisconsin, Shepard Pratt, Cleveland Clinic, Johns Hopkins University, and University of California San Francisco. The organization's founding members include B.More Inc., Compass Pathways, Lykos Therapeutics, and MindMed. APP's patient advocacy organization partners include Apollo Pact.
"Fostering strong collaboration between industry, academia, health care professionals, and policymakers can help advance scientific research into psychedelics and hopefully expand patient access to lasting and effective treatments," said Peter Hendricks, PhD, Professor and Heersink Endowed Chair of Psychiatry at the University of Alabama at Birmingham, who serves on as one of APP's scientific advisors. "Psychedelic research looks very promising for many treatment-resistant patients, and there is a good chance prescription psychedelic medicines will be a part of our healthcare system in the near future."
"As someone who credits psychedelic research with saving my life, I understand firsthand the life-changing effects of these treatments," added Kostas.
Visit psychedelicsRX.org to learn more.
About the Association for Prescription Psychedelics
The Association for Prescription Psychedelics (APP) works to educate and advocate for the development and accessibility of safe and effective prescription psychedelic medicines for patients. We serve as the trusted and recognized industry voice – at the national and state levels – on prescription psychedelic medicine and its integration into the healthcare system. Our education efforts help policymakers, regulators, and other key stakeholders learn about psychedelics and entactogens/empathogens and the associated medical conditions each compound may be able to treat. Our advocacy efforts help advance responsible legislative and regulatory policies that drive innovation, increase funding for research, and enhance access and coverage for prescription psychedelic medicine. Learn more at psychedelicsRX.org.
SOURCE Association for Prescription Psychedelics
MomsSpaghetti
7日前
MindMed Appoints Gregg Pratt, Ph.D. as Chief Regulatory and Quality Assurance Officer
NEW YORK--(BUSINESS WIRE)-- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the appointment of Gregg A. Pratt, Ph.D., as Chief Regulatory and Quality Assurance Officer. Dr. Pratt will serve as a member of the Executive Committee and oversee the Company’s regulatory and quality functions, as well as its product registration strategies.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241118653031/en/
“We are thrilled to welcome Gregg to the MindMed team. His leadership will strengthen our capabilities and accelerate our progress as we prepare to launch three Phase 3 studies of MM120 orally disintegrating tablet (ODT) in generalized anxiety disorder (GAD) and major depressive disorder (MDD),” said Rob Barrow, Chief Executive Officer of MindMed. “Gregg’s deep expertise in leading the regulatory approvals of transformative psychiatric drugs—demonstrated by his recent leadership in the approval of the first novel schizophrenia treatment in decades—will be key as we advance our Phase 3 programs. His appointment also reflects our strong commitment to clinical and regulatory excellence as we aim for two potential approvals in the coming years and work to transform the treatment of brain health disorders.”
“The therapeutic potential of MM120 ODT, as demonstrated in the Phase 2b study results, inspired me to join MindMed in pursuing what could be one of the most meaningful breakthroughs in the field of psychiatry,” said Dr. Pratt. “With our Phase 3 trial initiations imminent, I am eager to collaborate with the team to ensure our regulatory approach supports continued execution of the Company’s strategy and, if approved, to deliver MM120 ODT as a novel, much-needed therapy for millions of patients living with GAD and MDD.”
Dr. Pratt brings more than three decades of experience in drug development, registration, and commercialization, with a distinguished career spanning multiple therapeutic areas including psychiatry, neurology, and cardiology. Dr. Pratt joins MindMed from Karuna Therapeutics, which Bristol Myers Squibb acquired in March 2024. At Karuna, he served as Senior Vice President of Regulatory Affairs and Quality Assurance, where he oversaw the regulatory submission and ultimate approval by the U.S. Food and Drug Administration of COBENFY™, the first product in four decades with a novel mechanism of action in schizophrenia. Before joining Karuna Therapeutics, Dr. Pratt held leadership positions at Lundbeck, Abbvie, Solvay, Collegium, Baxter, and Assertio Therapeutics, where he led regulatory affairs in drug, biologic, and combination product development strategies, as well as registration maintenance for approved products in global markets. Dr. Pratt has a Ph.D. in chemistry from West Virginia University and a Bachelor of Science degree from the University of Wyoming.
Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
In connection with his appointment as Chief Regulatory and Quality Assurance Officer, MindMed granted Dr. Pratt an inducement award consisting of an option to purchase an aggregate of 350,000 common shares of the Company (the "Option"), with an effective grant date of November 18, 2024. The Option has an exercise price equal to the closing price of MindMed’s common shares on November 15, 2024, the last trading day on which MindMed’s common shares traded prior to the date of the grant and will vest over a four-year period with 25% vesting on the first anniversary and the remaining 75% vesting in 36 equal monthly installments over the next three-year period thereafter, subject to his continued employment.
The inducement award to Dr. Pratt was granted as a material inducement to his employment and was approved by MindMed's Compensation Committee on August 31, 2024, in accordance with Rule 5635(c)(4) of The NASDAQ Stock Market LLC. The award was granted outside MindMed's equity incentive plans.
About MindMed
MindMed is a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways that play key roles in brain health. MindMed trades on NASDAQ under the symbol MNMD.
MomsSpaghetti
1週前
$MNMD - Institutional Ownership 74.64%
Active Positions
Holders Shares
Increased Positions
80
20,092,052
Decreased Positions
51
2,593,025
Held Positions
48
32,049,315
Total Institutional Shares
179
54,734,392
https://www.nasdaq.com/market-activity/stocks/mnmd/institutional-holdings
MomsSpaghetti
1週前
Commodore Capital now owns 9.9% of MindMed $MNMD
Total owned shares are 8,176,721
https://ir.stockpr.com/mindmed/sec-filings-email/content/0001493152-24-045841/formsc13ga.htm
Commodore Capital is a healthcare investment firm. We use a science-driven approach to invest in innovative companies that are developing medical products to meaningfully improve patients’ lives. The fund is designed to make long term investments in small-cap public and late-stage private biopharmaceutical companies.
They have achieved notable success with several investments in the biopharmaceutical sector. One significant win was their investment in BELLUS Health Inc., a biopharmaceutical company specializing in treatments for chronic cough and other hypersensitization disorders. Commodore Capital held approximately 5,128,557 shares of BELLUS Health, valued at $54.2 million, representing 8.7% of their portfolio as of November 2022.
Wallmine Notes for BELLUS
--
In April 2023, BELLUS Health was acquired by GSK plc for $2 billion, a substantial premium over its market value at the time. This acquisition likely resulted in a significant return on investment for Commodore Capital, given their substantial stake in BELLUS Health prior to the acquisition.
Another notable investment is Cogent Biosciences, a biotechnology company developing precision therapies for genetically defined diseases. Commodore Capital's stake in Cogent Biosciences was valued at $64.5 million, making up 10.4% of their portfolio as of November 2022.
Wallmine Notes for Cogent
--
While specific financial outcomes are not detailed, the substantial allocation suggests a strong performance and confidence in the company's prospects. These investments underscore Commodore Capital's strategic focus on identifying and supporting promising healthcare companies, leading to significant returns in the sector.
MomsSpaghetti
2週前
As it related to importation of Schedule II substances. MindMed got this. I had to do some digging, but to get for example their ODT LSD tablets into the US once approved they will have to follow:
DEA Form 357 - Application for Permit to Import Controlled Substances for Domestic and/or Scientific PurposesDEA Form 357 - Application for Permit to Import Controlled Substances for Domestic and/or Scientific Purposes
and
The importation must adhere to the regulations outlined in Title 21 of the Code of Federal Regulations (CFR), Part 1312. These regulations detail the procedures and requirements for importing controlled substances.
https://www.ecfr.gov/current/title-21/chapter-II/part-1312?toc=1
I am not concerned about this at all and you can bet their team is already on this ahead of approval or anything else. That is just smart business practice. Take this for what is is worth, but if LSD is rescheduled to CII and MindMed gets FDA approval they will get this.
For example for those still having doubts:
Cocaine is a Schedule II drug under the Controlled Substances Act, meaning it has a high potential for abuse and has an accepted medical use for treatment in the United States.
Cocaine is derived from the coca plant, which is primarily cultivated in South American countries such as Colombia, Peru, and Bolivia. For medical use in the U.S., pharmaceutical-grade cocaine is imported from these regions under strict regulatory oversight. Once imported, it is processed and packaged by pharmaceutical companies for medical distribution.
Several pharmaceutical companies are authorized to manufacture and distribute cocaine hydrochloride for medical purposes in the United States. These companies produce and package cocaine hydrochloride under strict regulatory oversight for use as a local anesthetic in specific medical procedures. Notable companies include:
Mallinckrodt Pharmaceuticals: Offers Cocaine Hydrochloride USP CII in various package sizes, such as 5 grams and 25 grams.
Lannett Company, Inc.: Manufactures Numbrino, a cocaine hydrochloride nasal solution approved by the FDA for use as a local anesthetic during nasal surgeries
Genus Lifesciences Inc.: Produces Goprelto, a cocaine hydrochloride nasal solution indicated for the induction of local anesthesia of the mucous membranes during diagnostic procedures and surgeries on or through the nasal cavities in adults.
Having said all that... MindMed gets either bought out just prior to approval or if approval happens. Even without a buyout and no revenue the company will be valued at billions. We are just getting started.
Hot Features
プレミアム
登録して、同じ考えを持つ投資家と議論するためのアクティブなフォーラムで相互作用するためのアクティブなフォーラムに参加してください。
Jack Torrance
2時間前
Loudanepro
5時間前
LORTAP KCOTS
2日前
